San Diego, CA -- (SBWIRE) -- 10/10/2016 -- An investigation on behalf of investors of Fusion Pharm Inc shares over potential securities laws violations by Fusion Pharm Inc in connection certain financial statements was announced.

Investors who purchased shares of Fusion Pharm Inc (OTCMKTS:FSPM), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Fusion Pharm Inc (OTCMKTS:FSPM) concerning whether a series of statements by Fusion Pharm Inc (OTCMKTS:FSPM regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On September 16, 2016, the Securities and Exchange Commission ("SEC") announced fraud charges against Fusion Pharm Inc and its CEO, Scott M. Dittman, among others, for allegedly misleading investors by recording and trumpeting revenues for purported sales of PharmPods by round-tripping money from illegal stock sales by hidden affiliates. Shares of Fusion Pharm Inc (OTCMKTS:FSPM) closed on October 7, 2016, at $0.0002 per share.

Those who purchased shares of Fusion Pharm Inc have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com